ClostraBio, Inc Email Format

Biotechnology ResearchIllinois, United States11-50 Employees

ClostraBio, Inc. operates in the biotechnology research sector with a focus on gut health. Based in Chicago, Illinois, the company develops dietary supplements and therapeutic candidates intended to support gut barrier integrity and reduce systemic inflammation, with a focus on inflammatory bowel disease and food allergy. Its lead program, CLB101, is described as a next-generation anaerobic probiotic that provides continuous, localized production of butyrate directly in the lower gut, addressing limitations of traditional butyrate supplements and conventional probiotics.

CLB101 is planned for launch as a probiotic supplement in Fall 2025 through direct channels and partner distribution, including collaboration with a health practitioner-focused brand. The company has been active since at least 2018, when seed financing was recorded, and in January 2026 it was recognized as an Up-and-Comer at the Chicago Innovation Awards.

Sign up for free to view info

Company overview Employee directory